Onur Yazdan Balçık

Onur Yazdan Balçık

Auto-generated profile, based on publicly available information

Onur Yazdan Balçık

Department of Medical Oncology, Faculty of Medicine, Alanya Alaaddin Keykubat University, Antalya, Turkey

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2025 in Therapeutic Advances in Medical Oncology
Verified
Journal Article
Open access
OKOgur Karhan
Ogur Karhan
SISerdar İlEri
Serdar İlEri
ZUZuhat Urakçı
Zuhat Urakçı
YSYasin Sezgin
Yasin Sezgin
ÜYÜmit Yıldırım
Ümit Yıldırım
STSezai TUNÇ
Sezai TUNÇ
Background: Metastatic gastric cancer (GC) and gastroesophageal junction (GEJ) cancer are associated with a poor prognosis. Recent advancements in treatment have incorporated trastuzumab, anti-PD-1 agents, and anti-claudin therapies alongside chemotherapy (ChT), significantly improving outcomes. Contemporary studies predominantly employ doublet ChT as the backbone for these regimens, although historically triplet ChT regimens have been favored, particularly in younger patients requiring rapid tumor shrinkage. Objective: The aim of this study was to compare the efficacy of mFOLFOX-6 and mDCF regimens in the treatment of advanced GC and GEJ adenocarcinoma. Design: This was a retrospective multicenter study. Methods: Patient data were obtained from the databases of 25 hospitals across Turkey. Demographic and clinicopathological characteristics were documented. Overall survival (OS) and progression-free survival (PFS) were analyzed using the Kaplan–Meier method, and group discrepancies were assessed with log-rank test. Results: A total of 493 patients were included in the analysis, with similar baseline characteristics between the two groups. The objective response rate was 36.3% in the mDCF group and 38% in the mFOLFOX-6 group ( p = 0.7). The median PFS was 6 months for mDCF and 7 months for mFOLFOX-6 ( p = 0.2), while the median OS was 12 months for mDCF and 11 months for mFOLFOX-6 ( p = 0.4). Grade 3–4 neutropenia occurred in 27.6% of patients treated with mDCF versus 17.8% with mFOLFOX-6 ( p = 0.01). Likewise, grade 3–4 anemia was more frequent in the mDCF group (9.5%) compared to the mFOLFOX-6 group (4.8%; p = 0.04). Conclusion: Modified FOLFOX-6 demonstrated comparable efficacy to mDCF in the treatment of advanced GC and GEJ adenocarcinoma. Moreover, mFOLFOX-6 was associated with a lower incidence of hematological adverse effects.

12 December 2024 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
OBOnur Yazdan Balçık
Onur Yazdan Balçık
FYFatih Yılmaz
Fatih Yılmaz

2 October 2024 in Heliyon
Verified
Journal Article
Open access
OAOmer Acar
Omer Acar
OBOnur Yazdan Balcik
Onur Yazdan Balcik
MÜMuslih Ürün
Muslih Ürün
TATUGAY AVCI
TUGAY AVCI
MSMustafa Sahbazlar
Mustafa Sahbazlar
AEAtike Pinar Erdogan
Atike Pinar Erdogan
The pivotal prognostic determinant for recurrence and survival in surgically treated gastric cancer (GC) patients remains the lymph node status. Despite the adoption of D2 lymph node dissection as the standard approach in recent years, its association with increased morbidity in elderly patients raises concerns. This study aims to explore the prognostic significance of the Positive Lymph Node Ratio (PLNR) score in the context of recurrence and survival among elderly patients with surgically treated GC. A retrospective review of files about surgically treated patients with GC was conducted. The prognostic impact of the PLNR score on overall survival (OS) was assessed through Receiver Operating Characteristic (ROC) analysis. The cut-off value for the PLNR, determined through ROC analysis, was identified as 0.138. This value serves as a crucial threshold, as it distinguishes patients with a higher risk of poor outcomes. Patients with a PLNR score of 0.138 or below exhibited a median OS of 111 months, whereas those with a PLNR score above 0.138 had a significantly lower median OS of 22 months (p = 0.004). Our findings revealed that the PLNR emerged as an independent predictor of survival and recurrence in patients undergoing GC resection.However, it's important to note that while valuable, the PLNR system has limitations. It does not encompass the T stage, a key factor in cancer staging. Therefore, it cannot be a direct substitute for the comprehensive information TNM staging provides. It should be used as a supplementary tool in predicting prognosis, particularly in elderly patients unsuitable for standard lymph node dissection.

13 February 2026 in Biomarkers
Verified
Journal Article
Closed access
IBIsmail Beypinar
Ismail Beypinar
OBOnur Yazdan Balçık
Onur Yazdan Balçık
SUSemiha Urvay
Semiha Urvay
MÜMuslih Ürün
Muslih Ürün
BEBerrak Mermit Ercek
Berrak Mermit Ercek
AKAziz Kurtulus
Aziz Kurtulus
AimInflammation and immune dysfunction significantly impact cancer progression and treatment responses. This retrospective study investigated inflammatory parameters and ferritin in predicting immunotherapy response in non-small cell lung cancer (NSCLC) patients.MethodsThe study included 199 patients with NSCLC who received nivolumab between 2018 and 2024 at five medical centers. Various inflammatory markers were also evaluated. Ferritin levels at diagnosis and pretreatment were also evaluated.ResultsROC curve analyses showed ferritin delta had high prognostic performance for PFS and OS, with AUC values of 0.70 and 0.73. PIV and PNI were significantly associated with PFS and OS. In Kaplan-Meier analyses, PNI was the most consistent prognostic factor. Low PNI (≤43.5) significantly associated with shorter OS (5.0 vs. 15.0 months, p = 0.001) and shorter PFS (4.0 vs. 8.0 months, p = 0.002). High mGPS (score 2) and elevated PIV showed significant prognostic value. In multivariate Cox regression, PNI demonstrated independent prognostic significance. Objective response rate was the strongest prognostic factor for PFS (HR = 0.188, 95%CI: 0.114-0.309, p < 0.001).ConclusionThese findings highlight the prognostic value of inflammatory and nutritional markers in patients with NSCLC receiving immunotherapy. PNI demonstrated the most consistent prognostic value across multiple analytical approaches and maintained significance in the multivariate analysis.

1 January 2025 in Journal of Gastric Cancer
Verified
Journal Article
Open access
PDF file
YIYusuf ILHAN
Yusuf ILHAN
HGHalil Göksel Güzel
Halil Göksel Güzel
OBOnur Yazdan Balcik
Onur Yazdan Balcik
Ilhan Y, et al. J Gastric Cancer. 2025 Mar;25:e19. https://doi.org/10.5230/jgc.2025.25.e19

19 February 2025 in European Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
IBIsmail Beypinar
Ismail Beypinar
SUSemiha Urvay
Semiha Urvay
MÜMuslih Ürün
Muslih Ürün
BEBerrak Mermit Ercek
Berrak Mermit Ercek
HDHACER DEMİR
HACER DEMİR
OBOnur Yazdan Balçık
Onur Yazdan Balçık